Information:
Fel:
ID
23813
Beskrivning
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00478634
Länk
https://clinicaltrials.gov/show/NCT00478634
Nyckelord
Versioner (1)
- 2017-07-14 2017-07-14 -
Uppladdad den
14 juli 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Colorectal Cancer NCT00478634
Eligibility Colorectal Cancer NCT00478634
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Cancer NCT00478634
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Age
Item
age ≥ 18 years old and ≤ 65 years old.
boolean
C0001779 (UMLS CUI [1])
Colorectal cancer metastatic | Primary tumor Excision
Item
patients with metastatic crc. confirmation of crc diagnosis by histological or cytological specimen from original resection of primary tumor.
boolean
C0948380 (UMLS CUI [1])
C0677930 (UMLS CUI [2,1])
C0728940 (UMLS CUI [2,2])
C0677930 (UMLS CUI [2,1])
C0728940 (UMLS CUI [2,2])
Disease Progression | FOLFOX Regimen | Fluorouracil | oxaliplatin | bevacizumab | Xeloda-Oxaliplatin Regimen | capecitabine
Item
patients who progressed despite prior therapy with folfox (5fu and oxaliplatin) plus bevacizumab or xelox (capecitabine and oxaliplatin) plus bevacizumab.
boolean
C0242656 (UMLS CUI [1])
C0392943 (UMLS CUI [2])
C0016360 (UMLS CUI [3])
C0069717 (UMLS CUI [4])
C0796392 (UMLS CUI [5])
C1956962 (UMLS CUI [6])
C0671970 (UMLS CUI [7])
C0392943 (UMLS CUI [2])
C0016360 (UMLS CUI [3])
C0069717 (UMLS CUI [4])
C0796392 (UMLS CUI [5])
C1956962 (UMLS CUI [6])
C0671970 (UMLS CUI [7])
Measurable Disease Quantity | X-Ray Computed Tomography | Magnetic Resonance Imaging | Physical Examination
Item
patients with at least one measurable lesion by recist as determined by computer tomography (ct) scan, magnetic resonance imaging (mri) or physical examination.
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0040405 (UMLS CUI [2])
C0024485 (UMLS CUI [3])
C0031809 (UMLS CUI [4])
C1265611 (UMLS CUI [1,2])
C0040405 (UMLS CUI [2])
C0024485 (UMLS CUI [3])
C0031809 (UMLS CUI [4])
WHO performance status scale
Item
patients with a who performance status of 0 or 1.
boolean
C1298650 (UMLS CUI [1])
Gilbert Disease | Glucuronidation Deficiency Bilirubin
Item
patients with gilbert's syndrome or any other syndrome associated with deficient glucoronidation of bilirubin.
boolean
C0017551 (UMLS CUI [1])
C1880989 (UMLS CUI [2,1])
C0011155 (UMLS CUI [2,2])
C0005437 (UMLS CUI [2,3])
C1880989 (UMLS CUI [2,1])
C0011155 (UMLS CUI [2,2])
C0005437 (UMLS CUI [2,3])
Patient Homozygous UGT1A1*28 Allele | Sequencing
Item
patients who are homozygous for the ugt1a1*28 allele as determined by sequencing.
boolean
C0030705 (UMLS CUI [1,1])
C0019904 (UMLS CUI [1,2])
C2825127 (UMLS CUI [1,3])
C1294197 (UMLS CUI [2])
C0019904 (UMLS CUI [1,2])
C2825127 (UMLS CUI [1,3])
C1294197 (UMLS CUI [2])
irinotecan
Item
patients who have received previous irinotecan-based therapy.
boolean
C0123931 (UMLS CUI [1])
mTOR Inhibitor
Item
prior treatment with an mtor inhibitor.
boolean
C2746052 (UMLS CUI [1])
Clinical Trial Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,2])